1
|
Nakamura Y, Ueno T, Takahashi N, Ichikawa D, Yamauchi A, Ozaki N. Early identification of postpartum depression using machine learning. Psychiatry Clin Neurosci 2024. [PMID: 38623000 DOI: 10.1111/pcn.13659] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/21/2023] [Revised: 02/06/2024] [Accepted: 02/17/2024] [Indexed: 04/17/2024]
Affiliation(s)
- Yukako Nakamura
- Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | | | - Nagahide Takahashi
- Department of Child and Adolescent Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | | | - Aya Yamauchi
- Psychiatry/Child and Adolescent Psychiatry, Nagoya University Hospital, Nagoya, Japan
| | - Norio Ozaki
- Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan
- Department of Child and Adolescent Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan
- Pathophysiology of Mental Disorders, Nagoya University Graduate School of Medicine, Nagoya, Japan
| |
Collapse
|
2
|
Iesato A, Ueno T, Takahashi Y, Kataoka A, Matsunaga Y, Saeki S, Ozaki Y, Inoue Y, Maeda T, Uehiro N, Kobayashi T, Sakai T, Takano T, Kogawa T, Kitano S, Ono M, Osako T, Ohno S. P145 Postpartum breast cancer diagnosed within 10 years of last childbirth is a prognostic factor for distant metastasis – analysis of lymphovascular invasion relating factors. Breast 2023. [DOI: 10.1016/s0960-9776(23)00262-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/15/2023] Open
|
3
|
Obama K, Fujimori M, Okamura M, Kadowaki M, Ueno T, Boku N, Mori M, Akechi T, Yamaguchi T, Oyamada S, Okizaki A, Miyaji T, Sakurai N, Uchitomi Y. Effectiveness of a facilitation programme using a mobile application for initiating advance care planning discussions between patients with advanced cancer and healthcare providers: protocol for a randomised controlled trial (J-SUPPORT 2104). BMJ Open 2023; 13:e069557. [PMID: 36977536 PMCID: PMC10069562 DOI: 10.1136/bmjopen-2022-069557] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/30/2023] Open
Abstract
INTRODUCTION Timely implementation of the discussion process of advance care planning (ACP) is recommended. The communication attitude of healthcare providers is critical in ACP facilitation; thus, improving their communication attitudes may reduce patient distress and unnecessary aggressive treatment while enhancing care satisfaction. Digital mobile devices are being developed for behavioural interventions owing to their low space and time restrictions and ease of information sharing. This study aims to evaluate the effectiveness of an intervention programme using an application intended to facilitate patient questioning behaviour on improving communication related to ACP between patients with advanced cancer and healthcare providers. METHODS AND ANALYSIS This study uses a parallel-group, evaluator-blind, randomised controlled trial design. We plan to recruit 264 adult patients with incurable advanced cancer at the National Cancer Centre in Tokyo, Japan. Intervention group participants use a mobile application ACP programme and undergo a 30 min interview with a trained intervention provider for discussions with the oncologist at the next patient visit, while control group participants continue their usual treatment. The primary outcome is the oncologist's communication behaviour score assessed using audiorecordings of the consultation. Secondary outcomes include communication between patients and oncologists and the patients' distress, quality of life, care goals and preferences, and medical care utilisation. We will use a full analysis set including the registered participant population who receive at least a part of the intervention. ETHICS AND DISSEMINATION The study protocol was reviewed and approved by the Scientific Advisory Board of the Japan Supportive, Palliative and Psychosocial Oncology Group (Registration No. 2104) and the Institutional Review Board of the National Cancer Centre Hospital (registration No. 2020-500). Written informed consent is obtained from the patients. The results of the trial will be published in peer-reviewed scientific journals and presented at scientific meetings. TRIAL REGISTRATION NUMBERS UMIN000045305, NCT05045040.
Collapse
Affiliation(s)
- Kyoko Obama
- Institute for Cancer Control, National Cancer Center Japan, Tokyo, Japan
| | - Maiko Fujimori
- Institute for Cancer Control, National Cancer Center Japan, Tokyo, Japan
| | - Masako Okamura
- Institute for Cancer Control, National Cancer Center Japan, Tokyo, Japan
| | - Midori Kadowaki
- Institute for Cancer Control, National Cancer Center Japan, Tokyo, Japan
| | | | - Narikazu Boku
- Department of Oncology and General Medicine, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan
| | - Masanori Mori
- Division of Palliative and Supportive Care, Seirei Mikatahara Hospital, Hamamatsu, Japan
| | - Tatsuo Akechi
- Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
| | - Takuhiro Yamaguchi
- Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan
| | | | - Ayumi Okizaki
- Institute for Cancer Control, National Cancer Center Japan, Tokyo, Japan
| | - Tempei Miyaji
- Institute for Cancer Control, National Cancer Center Japan, Tokyo, Japan
| | - Naomi Sakurai
- Cancer Survivors Recruiting Project, General Incorporated Association, Tokyo, Japan
| | - Yosuke Uchitomi
- Institute for Cancer Control, National Cancer Center Japan, Tokyo, Japan
- Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center Hospital, Chuo-ku, Japan
| |
Collapse
|
4
|
Watanabe Y, Kuroki T, Ichikawa D, Ozone M, Uchimura N, Ueno T. Effect of smartphone-based cognitive behavioral therapy app on insomnia: a randomized, double-blind study. Sleep 2023; 46:6821283. [PMID: 36355920 DOI: 10.1093/sleep/zsac270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2022] [Revised: 10/31/2022] [Indexed: 11/12/2022] Open
Abstract
STUDY OBJECTIVES This study assessed the effects and safety of the smartphone-based cognitive behavioral therapy for insomnia (CBT-I) app compared with the sham app. METHODS In this multicenter, double-blind, and parallel-group study, 175 patients with insomnia were randomized to a smartphone-based CBT-I app (Active, n = 87) or a sham app (Sham, n = 88) group. The primary endpoint was the change in Athens Insomnia Score (AIS) from baseline after 8 weeks of treatment. RESULTS The change in AIS (mean ± standard deviation) from baseline, assessed using a modified-intent-to-treat analysis, was -6.7 ± 4.4 in the Active group and -3.3 ± 4.0 in the Sham group. The difference in the mean change between the groups was -3.4 (p < .001), indicating a greater change in the Active group. The change in CGI-I from the baseline was 1.3 ± 0.8 in the Active group and 0.7 ± 0.8 in the Sham group (p < .001). The proportion of patients with an AIS less than 6 was 37.9% in the Active group and 10.2% in the Sham group (p < .001). As for the safety assessment, no adverse reactions or device failures were detected in the Active group. CONCLUSIONS This study demonstrated the effectiveness of a smartphone-based CBT-I system for treating insomnia. CLINICAL TRIAL REGISTRATION ID: jRCT2032210071; trial name: Sham (software)-controlled, multicenter, dynamic allocation, double-blinded study of non-medication therapy with a software Yukumi in patients with insomnia disorders (verification study); URL: https://jrct.niph.go.jp/en-latest-detail/jRCT2032210071.
Collapse
Affiliation(s)
| | | | | | - Motohiro Ozone
- Department of Neuropsychiatry, Kurume University School of Medicine, Fukuoka, Japan
| | - Naohisa Uchimura
- Department of Neuropsychiatry, Kurume University School of Medicine, Fukuoka, Japan
| | | |
Collapse
|
5
|
Sakamoto K, Hirano A, Hidaka R, Suzuki AZ, Ueno T, Furuta T. Elucidation of the working principle of a gene-directed caged HDAC inhibitor with cell-type selectivity. Chem Commun (Camb) 2022; 58:10484-10487. [PMID: 36040293 DOI: 10.1039/d2cc03552a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Histone deacetylases (HDACs) play crucial roles in the epigenetic regulation of gene expression. Here, we report CM-Bhc-SAHA, a novel caged HDAC inhibitor, genetically targeting cells of interest. Mammalian cells expressing porcine liver esterase led to the optochemical inhibition of endogenous HDAC activity when treated with CM-Bhc-SAHA and irradiated with 405 nm light.
Collapse
Affiliation(s)
- Kotoko Sakamoto
- Department of Biomolecular Science, Faculty of Science, Toho University, 2-2-1 Miyama, Funabashi, 274-8510, Japan.
| | - Ayumi Hirano
- Department of Biomolecular Science, Faculty of Science, Toho University, 2-2-1 Miyama, Funabashi, 274-8510, Japan.
| | - Rika Hidaka
- Department of Biomolecular Science, Faculty of Science, Toho University, 2-2-1 Miyama, Funabashi, 274-8510, Japan.
| | - Akinobu Z Suzuki
- Department of Biomolecular Science, Faculty of Science, Toho University, 2-2-1 Miyama, Funabashi, 274-8510, Japan.
| | - Taro Ueno
- Department of Biomolecular Science, Faculty of Science, Toho University, 2-2-1 Miyama, Funabashi, 274-8510, Japan.
| | - Toshiaki Furuta
- Department of Biomolecular Science, Faculty of Science, Toho University, 2-2-1 Miyama, Funabashi, 274-8510, Japan.
| |
Collapse
|
6
|
Ochi E, Tsuji K, Narisawa T, Shimizu Y, Kuchiba A, Suto A, Jimbo K, Takayama S, Ueno T, Sakurai N, Matsuoka YJ. Abstract P4-11-11: Effect of home-based smartphone-supported high-intensity interval training on cardiorespiratory fitness in breast cancer survivors: A randomized controlled trial of the habit-B program. Cancer Res 2022. [DOI: 10.1158/1538-7445.sabcs21-p4-11-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: A strategy for maintaining and/or improving cardiorespiratory fitness (CRF) in the growing population of cancer survivors is of major clinical importance in the COVID-19 era. With the aim of increasing CRF, recent studies have focused on the use of high-intensity interval training (HIIT) in supervised experimental settings, which appeared to be more beneficial than usual care in cancer survivors at all stages of treatment and aftercare. However, the effect of unsupervised HIIT on increasing CRF in breast cancer survivors is not known. Purpose: To determine whether the newly developed habit-B program, which involves home-based smartphone-supported HIIT using body-weight exercises, improves CRF in early-stage breast cancer survivors. We hypothesized that the habit-B program would improve VO2peak compared with a control group. Methods: This single-center, 12-week, parallel-group, single-blind, randomized controlled trial involved 50 women with stage I-IIa breast cancer, aged 20 to 59 years, who had completed initial treatment except for hormone therapy. Participants wore a smartwatch and were randomized to either the exercise or control group from May 27, 2019 through November 30, 2020. The planned sample size was 60 patients to detect the increase of 2.0 ml/kg/min change in VO2peak with a standard deviation of 2.6 ml/kg/min, one-sided significance level of 2.5% and 80% power. The exercise group underwent home-based HIIT using a smartphone and a Fitbit Versa thrice weekly for 12 weeks (three times per week). The primary outcome was the 12-week change in peak oxygen uptake (VO2peak; mL/kg/min) between the groups. Other outcomes included muscle strength, 6-min walk test, resting heart rate, physical activity, fatigue, safety, and quality of life. Results: Of the 50 participants, 44 (exercise group, n=23; control group, n=21) completed the CRF assessment and 6 did not because of issues related to the COVID-19 pandemic. The change in VO2peak increased significantly in the exercise group (0.9 [95%CI, 0.1 to 1.7]) compared with the control group (-0.8 [95%CI, -1.5 to -0.1]) (mean difference, 1.7 [95% CI, 0.7 to 2.7], p < .01). Leg strength also increased significantly in the exercise group compared with the control group (mean difference, 13.5 [95% CI, 2.9 to 24.1], p < .01). Changes in other outcomes were not significantly different between the groups. Conclusion: A home-based HIIT intervention can lead to improved cardiorespiratory fitness and muscle strength in early-stage breast cancer survivors; however, a multicenter pragmatic clinical trial is required to confirm the benefits of the habit-B program.
Table 1.Demographic and medical characteristicsCharacteristicshabit-B (n = 25)Control (n = 25)Age, mean (SD), y48 (6)49 (5)Body mass index, mean (SD), kg/m221.0 (2.2)20.9 (2.0)Diastolic blood pressure, mean (SD), mmHg78 (8)81 (10)Systolic blood pressure, mean (SD), mmHg119 (13)129 (11)Alcohol consumption, n (%)≤weekly8 (32)5 (20)1–6 drinks per week15 (60)19 (76)Daily2 (8)1 (4)Highest Education, n (%)Junior high school0 (0)1 (4)High school3 (12)0 (0)College or more22 (88)24 (96)Employment status, n (%)Full- or part-time worker21 (84)21 (84)On leave1 (4)0 (0)Housewife3 (12)4 (16)Time the patient can use for herself, n (%)<14 hours/week10 (40)5 (20)14–25 hours/week8 (32)11 (44)>25 hours/week7 (28)9 (36)Past history of medical illness, n (%)6 (24)6 (24)Breast cancer stageI18 (72)18 (72)IIA7 (28)7 (28)TumorEstrogen receptor positive24 (96)25 (100)Progesterone receptor positive24 (96)24 (96)HER2 positive1 (4)0 (0)Receiving hormone therapy, n (%)24 (96)23 (92)Tamoxifen, n (%)18 (72)18 (72)Anastrozole, n (%)1 (4)4 (16)Other, n (%)5 (20)1 (4)Receiving radiotherapy, n (%)11 (44)12 (48)Time since surgery, mean (SD) months5 (4)6 (4)
Table 2.Changes in cardiorespiratory fitness and muscle strength from baseline to week 12habit-B (n = 21)Control (n = 23)Between-group differenceMean (SD)Mean (SD)Mean (95% CI)ESpPrimary endpointVO2peak (ml/kg/min)Baseline25.0 (3.0)24.9 (4.6)Week 1225.9 (2.8)24.1 (4.0)Within-group difference0.9 (1.7)-0.8 (1.6)1.7 (0.7 to 2.7)1.06<0.01Secondary endpointCardiorespiratory fitness6-min walk test (m)Baseline586 (43)603 (59)Week 12615 (42)631 (68)Within-group difference30 (30)29 (40)1 (-21 to 23)0.260.93VO2peak (L/min)Baseline1.33 (0.18)1.32 (0.29)Week 121.39 (0.23)1.29 (0.26)Within-group difference0.06 (0.11)-0.03 (0.09)0.10 (0.03 to 0.16)0.95<0.01Muscle strengthGrip strength (kgw)Baseline22.4 (3.8)23.3 (4.2)Week 1223.2 (4.2)23.7 (3.4)Within-group difference0.8 (2.0)0.4 (2.1)0.4 (-0.9 to 1.6)0.260.53Leg press one-repetition maximum (kg)Baseline93.6 (24.3)98.7 (40.6)Week 12106.6 (26.7)98.2 (30.9)Within-group difference13.0 (15.9)-0.5 (18.1)13.5 (2.9 to 24.1)0.790.01Chair stand test (s)Baseline14.4 (3.2)13.7 (2.5)Week 1213.5 (2.9)13.3 (2.5)Within-group difference-0.9 (2.7)-0.4 (1.8)-0.5 (-1.9 to 0.9)-0.210.50
Citation Format: Eisuke Ochi, Katsunori Tsuji, Tomomi Narisawa, Yoichi Shimizu, Aya Kuchiba, Akihiko Suto, Kenjiro Jimbo, Shin Takayama, Taro Ueno, Naomi Sakurai, Yutaka J Matsuoka. Effect of home-based smartphone-supported high-intensity interval training on cardiorespiratory fitness in breast cancer survivors: A randomized controlled trial of the habit-B program [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P4-11-11.
Collapse
Affiliation(s)
- Eisuke Ochi
- Hosei University/National Cancer Center Japan, Tokyo, Japan
| | - Katsunori Tsuji
- Hosei University/Research Fellow of Japan Society for the Promotion of Science/National Cancer Center Japan, Tokyo, Japan
| | - Tomomi Narisawa
- Musashino University/National Cancer Center Japan, Tokyo, Japan
| | | | - Aya Kuchiba
- National Cancer Center Japan/Kanagawa University of Human Services, Tokyo, Japan
| | | | | | | | | | | | | |
Collapse
|
7
|
Ueno T, Ichikawa D, Shimizu Y, Narisawa T, Tsuji K, Ochi E, Sakurai N, Iwata H, Matsuoka YJ. Comorbid insomnia among breast cancer survivors and its prediction using machine learning: a nationwide study in Japan. Jpn J Clin Oncol 2021; 52:39-46. [PMID: 34718623 PMCID: PMC8721647 DOI: 10.1093/jjco/hyab169] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2021] [Accepted: 10/12/2021] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVE Insomnia is an increasingly recognized major symptom of breast cancer which can seriously disrupt the quality of life during and many years after treatment. Sleep problems have also been linked with survival in women with breast cancer. The aims of this study were to estimate the prevalence of insomnia in breast cancers survivors, clarify the clinical characteristics of their sleep difficulties and use machine learning techniques to explore clinical insights. METHODS Our analysis of data, obtained in a nationwide questionnaire survey of breast cancer survivors in Japan, revealed a prevalence of suspected insomnia of 37.5%. With the clinical data obtained, we then used machine learning algorithms to develop a classifier that predicts comorbid insomnia. The performance of the prediction model was evaluated using 8-fold cross-validation. RESULTS When using optimal hyperparameters, the L2 penalized logistic regression model and the XGBoost model provided predictive accuracy of 71.5 and 70.6% for the presence of suspected insomnia, with areas under the curve of 0.76 and 0.75, respectively. Population segments with high risk of insomnia were also extracted using the RuleFit algorithm. We found that cancer-related fatigue is a predictor of insomnia in breast cancer survivors. CONCLUSIONS The high prevalence of sleep problems and its link with mortality warrants routine screening. Our novel predictive model using a machine learning approach offers clinically important insights for the early detection of comorbid insomnia and intervention in breast cancer survivors.
Collapse
Affiliation(s)
| | | | - Yoichi Shimizu
- Division of Health Care Research, Behavioral Science and Survivorship Research Group, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan.,Division of Nursing, National Cancer Center Hospital, Tokyo, Japan
| | - Tomomi Narisawa
- Division of Health Care Research, Behavioral Science and Survivorship Research Group, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
| | - Katsunori Tsuji
- Division of Health Care Research, Behavioral Science and Survivorship Research Group, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
| | - Eisuke Ochi
- Faculty of Bioscience and Applied Chemistry, Hosei University, Koganei, Tokyo, Japan
| | | | - Hiroji Iwata
- Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - Yutaka J Matsuoka
- Division of Health Care Research, Behavioral Science and Survivorship Research Group, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
| |
Collapse
|
8
|
Tanaka Y, Takeuchi H, Nakashima Y, Nagano H, Ueno T, Tomizuka K, Morita S, Emi Y, Hamai Y, Hihara J, Saeki H, Oki E, Kunisaki C, Otsuji E, Baba H, Matsubara H, Maehara Y, Kitagawa Y, Yoshida K. Effects of an elemental diet to reduce adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil: a phase III randomized controlled trial-EPOC 2 (JFMC49-1601-C5). ESMO Open 2021; 6:100277. [PMID: 34626918 PMCID: PMC8511839 DOI: 10.1016/j.esmoop.2021.100277] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2021] [Revised: 09/03/2021] [Accepted: 09/07/2021] [Indexed: 01/11/2023] Open
Abstract
Background Oral mucositis (OM) is an unpleasant adverse event in patients receiving chemotherapy. A prospective feasibility study showed that elemental diet (ED), an oral supplement that does not require digestion, may prevent OM. Based on this, we established a central review system for oral cavity assessment by dental oncology specialists blinded to background data. We used this system to elucidate the preventive effect of an ED against OM in patients with esophageal cancer receiving docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy. Patients and methods In this phase III, multicenter, parallel-group, controlled trial, patients consuming a normal diet orally were randomly assigned (1 : 1) to receive two cycles of DCF with (group A) or without (group B) an ED (Elental® 160 g/day). We assessed the incidence of grade ≥2 OM evaluated by two reviewers, changes in body weight, prealbumin, C-reactive protein, and DCF completion rate based on ED compliance. Results Of the 117 patients randomly assigned to treatment, four failed to start treatment and were excluded from the primary analysis; thus, groups A and B comprised 55 and 58 patients, respectively. There were no significant differences in background characteristics. Grade ≥2 OM was observed in eight (15%) and 20 (34%) patients in groups A and B, respectively (P = 0.0141). Changes in body weight and prealbumin during the two DCF cycles were significantly higher in group A than B (P = 0.0022 and 0.0203, respectively). During the first cycle, changes in C-reactive protein were significantly lower in group A than B (P = 0.0338). In group A (receiving ED), the DCF completion rate was 100% in patients with 100% ED compliance and 70% in patients failing ED completion (P = 0.0046). Conclusions The study findings demonstrate that an ED can prevent OM in patients with esophageal cancer receiving chemotherapy. Patients receiving docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy commonly develop oral mucositis (OM). An elemental diet (ED) was able to prevent OM in patients with esophageal cancer receiving DCF. Grade ≥2 OM was observed in 15% of patients receiving the ED versus 34% of those not receiving the ED (P = 0.0141). Body weight was maintained in the ED group, and hematologic toxicities were lower, compared with the non-ED group. The DCF completion rate significantly correlated with ED compliance (P = 0.0046).
Collapse
Affiliation(s)
- Y Tanaka
- Department of Surgical Oncology, Graduate School of Medicine, Gifu University, Gifu, Japan
| | - H Takeuchi
- Department of Surgery, School of Medicine, Hamamatsu University, Hamamatsu, Japan
| | - Y Nakashima
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - H Nagano
- Gastroenterological, Breast and Endocrine Surgery, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan
| | - T Ueno
- Department of Dentistry, National Cancer Center Hospital, Tokyo, Japan
| | - K Tomizuka
- Department of Dentistry, Cancer Institute Hospital of JFCR, Tokyo, Japan
| | - S Morita
- Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Y Emi
- Department of Surgery, Saiseikai Fukuoka General Hospital, Fukuoka, Japan
| | - Y Hamai
- Department of Surgical Oncology, Hiroshima University Hospital, Hiroshima, Japan
| | - J Hihara
- Department of Surgery, Hiroshima City Asa Citizens Hospital, Hiroshima, Japan
| | - H Saeki
- Department of General Surgical Science, Gunma University, Maebashi, Japan
| | - E Oki
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - C Kunisaki
- Department of Surgery, Gastroenterological Center, Yokohama City University, Yokohama, Japan
| | - E Otsuji
- Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - H Baba
- Department of Gastroenterological Surgery, Kumamoto University, Kumamoto, Japan
| | - H Matsubara
- Department of Frontier Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Y Maehara
- Director, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan
| | - Y Kitagawa
- Department of Surgery, Keio University School of Medicine, Tokyo, Japan
| | - K Yoshida
- Department of Surgical Oncology, Graduate School of Medicine, Gifu University, Gifu, Japan.
| |
Collapse
|
9
|
Ueno T, Kitano S, Masuda N, Ikarashi D, Yamashita M, Kadoya T, Bando H, Yamanaka T, Ohtani S, Nagai S, Nakayama T, Takahashi M, Saji S, Aogi K, Velaga R, Kawaguchi K, Morita S, Haga H, Ohno S, Toi M. 1776P Immune microenvironment, homologous recombination deficiency and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: JBCRG22 TR. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1720] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
10
|
Kawaguchi K, Masuda N, Tanaka S, Bando H, Nishimura T, Kadoya T, Yamanaka T, Imoto S, Velaga R, Tamura N, Aruga T, Maeshima Y, Takada M, Suzuki E, Ueno T, Ogawa S, Haga H, Ohno S, Morita S, Toi M. 1766P Longitudinal alteration of cytokine profile in the peripheral blood and clinical response for neoadjuvant chemotherapy in triple-negative breast cancer patients (translational research of the JBCRG-22 trial). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
11
|
Ochi E, Tsuji K, Narisawa T, Shimizu Y, Kuchiba A, Suto A, Jimbo K, Takayama S, Ueno T, Sakurai N, Matsuoka Y. Cardiorespiratory fitness in breast cancer survivors: a randomised controlled trial of home-based smartphone supported high intensity interval training. BMJ Support Palliat Care 2021; 12:33-37. [PMID: 34389552 PMCID: PMC8862092 DOI: 10.1136/bmjspcare-2021-003141] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2021] [Accepted: 06/04/2021] [Indexed: 11/03/2022]
Abstract
BACKGROUND A strategy for maintaining and/or improving cardiorespiratory fitness (CRF) in the growing population of cancer survivors is of major clinical importance, especially in the COVID-19 era. The effect of unsupervised high-intensity interval training (HIIT) on increasing CRF in breast cancer survivors is unknown. PURPOSE The purpose of this study was to determine whether the newly developed habit-B programme, which involves home-based smartphone-supported HIIT using body weight exercises, improves CRF in early-stage breast cancer survivors. METHODS This single-centre, 12-week, parallel-group, single-blind, randomised controlled trial involved 50 women with stage I-IIa breast cancer, aged 20-59 years, who had completed initial treatment except for hormone therapy. Participants were randomised to either the exercise or control group. The primary outcome was the 12-week change in peak oxygen uptake [Formula: see text]. Other outcomes included muscle strength, 6 min walk test, resting heart rate, physical activity, fatigue, safety and quality of life. RESULTS The change in [Formula: see text] and leg strength increased significantly in the exercise group compared with the control group (p<0.01). Changes in other outcomes were not significantly different between the groups. CONCLUSION A home-based HIIT intervention can lead to improve CRF and muscle strength in early-stage breast cancer survivors.
Collapse
Affiliation(s)
- Eisuke Ochi
- Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Chuo-ku, Tokyo, Japan .,Faculty of Bioscience and Applied Chemistry, Hosei University, Koganei, Tokyo, Japan
| | - Katsunori Tsuji
- Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Chuo-ku, Tokyo, Japan
| | - Tomomi Narisawa
- Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Chuo-ku, Tokyo, Japan
| | - Yoichi Shimizu
- Division of Nursing, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
| | - Aya Kuchiba
- Biostatistics Division, Center for Research Administration and Support, National Cancer Center Japan, Chuo-ku, Tokyo, Japan.,Division of Biostatistical Research, Center for Public Health Sciences, National Cancer Center Japan, Chuo-ku, Tokyo, Japan
| | - Akihiko Suto
- Division of Breast Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
| | - Kenjiro Jimbo
- Division of Breast Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
| | - Shin Takayama
- Division of Breast Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
| | | | | | - Yutaka Matsuoka
- Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Chuo-ku, Tokyo, Japan
| |
Collapse
|
12
|
Abstract
After the accident at Fukushima Daiichi nuclear power plant on 11 March 2011, radioactive materials were released into the atmosphere resulting in environmental contamination. Following the implementation of environmental decontamination efforts, the Radiation Dose Registration Centre of the Radiation Effects Association established the radiation dose registration system for decontamination and related workers to consolidate and prevent the loss of radiation records. This article presents statistics on the radiation doses of decontamination and related workers using official records. Since approximately 10 years have passed since the accident in Fukushima, the types of work conducted in the affected restricted areas have changed over time. Therefore, changes in radiation dose for each type of work and comparisons with nuclear workers are presented.
Collapse
Affiliation(s)
- T Ogawa
- Radiation Effects Association, 1-9-16 Kaji-cho, Chiyoda-ku, Tokyo 101-0044, Japan
| | - T Ueno
- Radiation Effects Association, 1-9-16 Kaji-cho, Chiyoda-ku, Tokyo 101-0044, Japan
| | - T Asano
- Radiation Effects Association, 1-9-16 Kaji-cho, Chiyoda-ku, Tokyo 101-0044, Japan
| | - A Suzuki
- Radiation Effects Association, 1-9-16 Kaji-cho, Chiyoda-ku, Tokyo 101-0044, Japan
| | - A Ito
- Radiation Effects Association, 1-9-16 Kaji-cho, Chiyoda-ku, Tokyo 101-0044, Japan
| |
Collapse
|
13
|
Hasegawa M, Taira M, Kanaya T, Araki K, Watanabe T, Tominaga Y, Kugo Y, Ishida H, Narita A, Ueno T, Ueno T, Sawa Y. Clinical Outcomes for Children with Left Ventricular Noncompaction and Cardiomyopathy. J Heart Lung Transplant 2021. [DOI: 10.1016/j.healun.2021.01.810] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
14
|
Mitsui T, Sakai S, Li S, Ueno T, Watanuki T, Kobayashi Y, Masuda R, Seto M, Akai H. Magnetic Friedel Oscillation at the Fe(001) Surface: Direct Observation by Atomic-Layer-Resolved Synchrotron Radiation ^{57}Fe Mössbauer Spectroscopy. Phys Rev Lett 2020; 125:236806. [PMID: 33337194 DOI: 10.1103/physrevlett.125.236806] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/09/2020] [Revised: 07/13/2020] [Accepted: 10/16/2020] [Indexed: 06/12/2023]
Abstract
The surface magnetism of Fe(001) was studied in an atomic layer-by-layer fashion by using the in situ iron-57 probe layer method with a synchrotron Mössbauer source. The observed internal hyperfine field H_{int} exhibits a marked decrease at the surface and an oscillatory behavior with increasing depth in the individual upper four layers below the surface. The calculated layer-depth dependencies of the effective hyperfine field |H_{eff}|, isomer shift δ, and quadrupole shift 2ϵ agree well with the observed experimental parameters. These results provide the first experimental evidence for the magnetic Friedel oscillations, which penetrate several layers from the Fe(001) surface.
Collapse
Affiliation(s)
- T Mitsui
- National Institutes for Quantum and Radiological Science and Technology, Sayo, Hyogo 679-5148, Japan
- National Institutes for Quantum and Radiological Science and Technology, Takasaki, Gunma 370-1292, Japan
| | - S Sakai
- National Institutes for Quantum and Radiological Science and Technology, Takasaki, Gunma 370-1292, Japan
| | - S Li
- National Institutes for Quantum and Radiological Science and Technology, Takasaki, Gunma 370-1292, Japan
| | - T Ueno
- National Institutes for Quantum and Radiological Science and Technology, Sayo, Hyogo 679-5148, Japan
- National Institutes for Quantum and Radiological Science and Technology, Takasaki, Gunma 370-1292, Japan
| | - T Watanuki
- National Institutes for Quantum and Radiological Science and Technology, Sayo, Hyogo 679-5148, Japan
- National Institutes for Quantum and Radiological Science and Technology, Takasaki, Gunma 370-1292, Japan
| | - Y Kobayashi
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Asashironishi, Kumatori, Osaka 590-0494, Japan
| | - R Masuda
- Faculty of Science and Technology, Hirosaki University, Bunkyocho, Hirosaki, Aomori 036-8152, Japan
| | - M Seto
- National Institutes for Quantum and Radiological Science and Technology, Sayo, Hyogo 679-5148, Japan
- Institute for Integrated Radiation and Nuclear Science, Kyoto University, Asashironishi, Kumatori, Osaka 590-0494, Japan
| | - H Akai
- The Institute for Solid State Physics, The University of Tokyo, Kashiwa, Chiba 277-8581, Japan
| |
Collapse
|
15
|
Araki K, Miyagawa S, Kawamura T, Ishii R, Harada A, Ueno T, Toda K, Kuratani T, Sawa Y. Autologous skeletal myoblast sheet prevents cardiomyocyte ischemia and right heart dysfunction in pressure-overloaded right heart porcine model. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Severe heart failure (HF) with congenital heart disease (CHD) have demonstrated life threatening disorder despite of remarkable progress in medical therapies. Autologous skeletal myoblast sheet transplantation therapy showed clinical efficacy for left ventricular dysfunction by cytokine paracrine effects, which are expected to be sufficiently effective against right ventricular (RV) dysfunction which is often seen in end-stage of CHD patients with severe HF.
Hypothesis
An autologous skeletal myoblast sheet transplantation alleviates RV dysfunction in a pressure-overloaded right heart in a porcine model.
Methods
Five-to-six-month-old Göttingen mini-pigs underwent pulmonary artery banding with vascular occluding system. To create the porcine model of chronic pressure-overloaded right heart, vascular occluding system was gradually inflated, over a month, to make pulmonary stenosis to banding velocity >3.0 m/s measured by echocardiography (UCG), and then fixed for another month. Two months after banding, autologous skeletal myoblast sheet was placed on the epicardium of the RV free wall and followed for 2 months. Groups were as follows: control (C, n=5), sheet implantation (S, n=5). Cardiac function was measured using UCG, cardiac computed tomography (CT), and cardiac catheterization (Cath). Two months after sheet implantation, hearts were dissected for histologic analysis.
Results
Before sheet implantation, RV dysfunction was equal in groups; however, 2 months after sheet implantation, RV dysfunction and myocardial ischemia was significantly ameliorated in group S than group C. On CT, RV ejection fraction exacerbation were well controlled in Group S compared to Group C (S 44.9±2.2 vs C 31.9±2.1% [p=0.0042]). UCG and Cath revealed well maintained systolic and diastolic function in Group S compared to Group C (Tei index: S 0.42±0.06 vs C 0.70±0.07 [p=0.0240], Fraction Area Change: S 45.8±7.8 vs C 19.5±1.3% [p=0.0240], Isovolumic Relaxation Time; S 44.3±9.2 vs C 97.3±9.5 ms [p=0.0304]). On C11-Acetate Positron Emission Tomography, myocardial ischemia was more prominent in Group C compared to Group S (K mono-Rest/Stress: S 3.17±0.69 vs C 2.03±0.65 min-1 [p=0.0421], Myocardial Blood Flow-Rest/Stress: S 3.22±0.39 vs C 2.13±0.92 min-1 [p=0.0421]). In histologic analysis, Group S presented less progressed hypertrophic change in periodic acid-Schiff stain (S 13.5±0.9 vs C 18.0±3.0 μg [p=0.0240]), anti-fibrotic changes in picrosirius red stain (S 3.0±0.3 vs C 4.2±0.2% [p=0.0421]), more angiogenesis in CD31 expression (S 18.3±1.5 vs C 10.7±2.8 / 104 μm2 [p=0.0240]), and less production of reactive oxygen species in fluorescent immunostaining (S 5.9±1.7 vs C 18.4±1.7% [p=0.0304]).
Conclusion
Autologous skeletal myoblast sheet transplantation alleviates cardiomyocyte Ischemia and RV dysfunction in a porcine model of pressure-overloaded right heart.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- K Araki
- Osaka University, Osaka, Japan
| | | | | | - R Ishii
- Osaka University, Osaka, Japan
| | | | - T Ueno
- Osaka University, Osaka, Japan
| | - K Toda
- Osaka University, Osaka, Japan
| | | | - Y Sawa
- Osaka University, Osaka, Japan
| |
Collapse
|
16
|
Baba F, Shibamoto Y, Iwana M, Saito K, Nagayoshi J, Ono Y, Akiyama K, Fujioka R, Ueno T, Horita R, Inada A, Hayakawa T. Changes of Bone Strength Evaluated by CT-based Finite Element Methods in Radiotherapy for Bone Metastases of the Proximal Femur. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
17
|
Takeuchi H, Tanaka Y, Nakashima Y, Otsuji E, Nagano H, Matsubara H, Baba H, Emi Y, Oki E, Ueno T, Tomizuka K, Morita S, Kunisaki C, Hihara J, Saeki H, Hamai Y, Maehara Y, Kitagawa Y, Yoshida K. 1425MO Effects of elemental diet for gastrointestinal adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil (EPOC 2 study: JFMC49-1601-C5): A phase III randomized controlled trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
18
|
Inoue T, Ichikawa D, Ueno T, Cheong M, Inoue T, Whetstone WD, Endo T, Nizuma K, Tominaga T. XGBoost, a Machine Learning Method, Predicts Neurological Recovery in Patients with Cervical Spinal Cord Injury. Neurotrauma Rep 2020; 1:8-16. [PMID: 34223526 PMCID: PMC8240917 DOI: 10.1089/neur.2020.0009] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
The accurate prediction of neurological outcomes in patients with cervical spinal cord injury (SCI) is difficult because of heterogeneity in patient characteristics, treatment strategies, and radiographic findings. Although machine learning algorithms may increase the accuracy of outcome predictions in various fields, limited information is available on their efficacy in the management of SCI. We analyzed data from 165 patients with cervical SCI, and extracted important factors for predicting prognoses. Extreme gradient boosting (XGBoost) as a machine learning model was applied to assess the reliability of a machine learning algorithm to predict neurological outcomes compared with that of conventional methodology, such as a logistic regression or decision tree. We used regularly obtainable data as predictors, such as demographics, magnetic resonance variables, and treatment strategies. Predictive tools, including XGBoost, a logistic regression, and a decision tree, were applied to predict neurological improvements in the functional motor status (ASIA [American Spinal Injury Association] Impairment Scale [AIS] D and E) 6 months after injury. We evaluated predictive performance, including accuracy and the area under the receiver operating characteristic curve (AUC). Regarding predictions of neurological improvements in patients with cervical SCI, XGBoost had the highest accuracy (81.1%), followed by the logistic regression (80.6%) and the decision tree (78.8%). Regarding AUC, the logistic regression showed 0.877, followed by XGBoost (0.867) and the decision tree (0.753). XGBoost reliably predicted neurological alterations in patients with cervical SCI. The utilization of predictive machine learning algorithms may enhance personalized management choices through pre-treatment categorization of patients.
Collapse
Affiliation(s)
- Tomoo Inoue
- Department of Neurosurgery, National Health Organization Sendai Medical Center, Sendai, Miyagi, Japan
| | | | | | - Maxwell Cheong
- Department of Radiology, Stanford University School of Medicine, Palo Alto, California, USA
| | - Takashi Inoue
- Department of Neurosurgery, National Health Organization Sendai Medical Center, Sendai, Miyagi, Japan
| | - William D. Whetstone
- Department of Emergency Medicine, University of California, San Francisco, San Francisco, California, USA
| | - Toshiki Endo
- Department of Neurosurgery, National Health Organization Sendai Medical Center, Sendai, Miyagi, Japan
- Department of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - Kuniyasu Nizuma
- Department of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
- Department of Neurosurgical Engineering and Translational Neuroscience, Graduate School of Biomedical Engineering, Tohoku University, Sendai, Miyagi, Japan
- Department of Neurosurgical Engineering and Translational Neuroscience, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| | - Teiji Tominaga
- Department of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan
| |
Collapse
|
19
|
Hirano T, Motohashi T, Okumura K, Takajo K, Kuroki T, Ichikawa D, Matsuoka Y, Ochi E, Ueno T. Data Validation and Verification Using Blockchain in a Clinical Trial for Breast Cancer: Regulatory Sandbox. J Med Internet Res 2020; 22:e18938. [PMID: 32340974 PMCID: PMC7298640 DOI: 10.2196/18938] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2020] [Revised: 04/27/2020] [Accepted: 04/27/2020] [Indexed: 01/16/2023] Open
Abstract
Background The integrity of data in a clinical trial is essential, but the current data management process is too complex and highly labor-intensive. As a result, clinical trials are prone to consuming a lot of budget and time, and there is a risk for human-induced error and data falsification. Blockchain technology has the potential to address some of these challenges. Objective The aim of the study was to validate a system that enables the security of medical data in a clinical trial using blockchain technology. Methods We have developed a blockchain-based data management system for clinical trials and tested the system through a clinical trial for breast cancer. The project was conducted to demonstrate clinical data management using blockchain technology under the regulatory sandbox enabled by the Japanese Cabinet Office. Results We verified and validated the data in the clinical trial using the validation protocol and tested its resilience to data tampering. The robustness of the system was also proven by survival with zero downtime for clinical data registration during a Amazon Web Services disruption event in the Tokyo region on August 23, 2019. Conclusions We show that our system can improve clinical trial data management, enhance trust in the clinical research process, and ease regulator burden. The system will contribute to the sustainability of health care services through the optimization of cost for clinical trials.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Yutaka Matsuoka
- Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
| | - Eisuke Ochi
- Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan.,Faculty of Bioscience and Applied Chemistry, Hosei University, Tokyo, Japan
| | | |
Collapse
|
20
|
Samura T, Yoshioka D, Toda K, Miyagawa S, Yoshikawa Y, Hata H, Kainuma S, Kawamura T, Kawamura A, Ueno T, Kuratani T, Sawa Y. Impact of Inhalation of Nitric Oxide and Extubation on Hemodynamics of Right Heart in Acute Phase after Left Ventricular Assist Device Implantation. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
21
|
Shimizu Y, Tsuji K, Ochi E, Arai H, Okubo R, Kuchiba A, Shimazu T, Sakurai N, Narisawa T, Ueno T, Iwata H, Matsuoka Y. Study protocol for a nationwide questionnaire survey of physical activity among breast cancer survivors in Japan. BMJ Open 2020; 10:e032871. [PMID: 31964669 PMCID: PMC7044853 DOI: 10.1136/bmjopen-2019-032871] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/13/2019] [Revised: 11/15/2019] [Accepted: 12/16/2019] [Indexed: 01/07/2023] Open
Abstract
INTRODUCTION A major concern is that few cancer survivors meet the guidelines for recommended levels of physical activity. No studies have investigated physical activity among breast cancer survivors nationwide in Japan. Therefore, the aims of this study are to identify the levels of physical activity among breast cancer survivors, to examine factors-related physical activity among breast cancer survivors and to identify breast cancer survivors' preferences for and interest in exercise programmes in order to inform the future programme development. METHODS AND ANALYSIS We will administer a cross-sectional survey using a self-report questionnaire to breast cancer survivors. At each of 50 facilities selected to include a variety of institutional backgrounds according to the population distribution of different regions throughout Japan, we will consecutively distribute the questionnaire to 30 outpatients who have completed initial treatments, except for hormone therapy. The target sample size is 1500 survivors. We will calculate descriptive statistics for each measurement item and perform univariate and multivariate analyses using outcome measures (eg, physical activity and quality of life) related to physical, psychological, social and environmental factors. DISCUSSION This is the first nationwide survey of physical activity levels among breast cancer survivors in Japan. Identifying the factors associated with physical activity will help us to develop, disseminate and implement programmes that encourage more survivors to adhere to physical activity guidelines. ETHICS AND DISSEMINATION The protocol was approved by the Institutional Review Board (IRB) of the National Cancer Center on 11 January 2019 (ID: 2018-295). In addition, many of the participating facilities required ethical approval from their local IRBs, while others did not. Accordingly, approval from the local IRBs of individual facilities was obtained when required. The findings will be disseminated through peer-reviewed publications and conference presentations.
Collapse
Affiliation(s)
- Yoichi Shimizu
- Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
- Department of Nursing, National Cancer Center Hospital, Tokyo, Japan
| | - Katsunori Tsuji
- Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
| | - Eisuke Ochi
- Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
- Faculty of Bioscience and Applied Chemistry, Hosei University, Koganei, Tokyo, Japan
| | - Hirokazu Arai
- Department of Psychology, Faculty of Letters, Hosei University, Chiyoda-ku, Tokyo, Japan
| | - Ryo Okubo
- Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
| | - Aya Kuchiba
- Division of Biostatistical Research, Center for Public Health Sciences, National Cancer Center Japan, Chuo-ku, Tokyo, Japan
- Biostatistics Division, Center for Research Administration and Support, National Cancer Center Hospital, Tokyo, Chuo-ku, Japan
| | - Taichi Shimazu
- Division of Prevention, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Chuo-ku, Japan
| | | | - Tomomi Narisawa
- Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
| | | | - Hiroji Iwata
- Department of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
| | - Yutaka Matsuoka
- Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
- Lifestyle Medicine, Cooperative Graduate Program, The Jikei University Graduate School of Medicine, Tokyo, Japan
| |
Collapse
|
22
|
Akiba M, Sugimoto K, Aoki R, Murakami R, Miyashita T, Hashimoto R, Hiranuma A, Yamauchi J, Ueno T, Morimoto T. Dopamine modulates the optomotor response to unreliable visual stimuli in Drosophila melanogaster. Eur J Neurosci 2019; 51:822-839. [PMID: 31834948 DOI: 10.1111/ejn.14648] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2019] [Revised: 11/18/2019] [Accepted: 12/05/2019] [Indexed: 01/21/2023]
Abstract
State-dependent modulation of sensory systems has been studied in many organisms and is possibly mediated through neuromodulators such as monoamine neurotransmitters. Among these, dopamine is involved in many aspects of animal behaviour, including movement control, attention, motivation and cognition. However, the precise neural mechanism underlying dopaminergic modulation of behaviour induced by sensory stimuli remains poorly understood. Here, we used Drosophila melanogaster to show that dopamine can modulate the optomotor response to moving visual stimuli including noise. The optomotor response is the head-turning response to moving objects, which is observed in most sight-reliant animals including mammals and insects. First, the effects of the dopamine system on the optomotor response were investigated in mutant flies deficient in dopamine receptors D1R1 or D1R2, which are involved in the modulation of sleep-arousal in flies. We examined the optomotor response in D1R1 knockout (D1R1 KO) and D1R2 knockout (D1R2 KO) flies and found that it was not affected in D1R1 KO flies; however, it was significantly reduced in D1R2 KO flies compared with the wild type. Using cell-type-specific expression of an RNA interference construct of D1R2, we identified the fan-shaped body, a part of the central complex, responsible for dopamine-mediated modulation of the optomotor response. In particular, pontine cells in the fan-shaped body seemed important in the modulation of the optomotor response, and their neural activity was required for the optomotor response. These results suggest a novel role of the central complex in the modulation of a behaviour based on the processing of sensory stimulations.
Collapse
Affiliation(s)
- Masumi Akiba
- Laboratory of Molecular Neuroscience and Neurology, School of Life Sciences, University of Pharmacy and Life Sciences, Tokyo, Japan
| | - Kentaro Sugimoto
- Laboratory of Molecular Neuroscience and Neurology, School of Life Sciences, University of Pharmacy and Life Sciences, Tokyo, Japan.,Department of Computer Science, School of Computing, Tokyo Institute of Technology, Tokyo, Japan
| | - Risa Aoki
- Laboratory of Molecular Neuroscience and Neurology, School of Life Sciences, University of Pharmacy and Life Sciences, Tokyo, Japan
| | - Ryo Murakami
- Laboratory of Molecular Neuroscience and Neurology, School of Life Sciences, University of Pharmacy and Life Sciences, Tokyo, Japan
| | | | - Riho Hashimoto
- Laboratory of Molecular Neuroscience and Neurology, School of Life Sciences, University of Pharmacy and Life Sciences, Tokyo, Japan
| | - Anna Hiranuma
- Laboratory of Molecular Neuroscience and Neurology, School of Life Sciences, University of Pharmacy and Life Sciences, Tokyo, Japan
| | - Junji Yamauchi
- Laboratory of Molecular Neuroscience and Neurology, School of Life Sciences, University of Pharmacy and Life Sciences, Tokyo, Japan
| | - Taro Ueno
- Department of Biomolecular Science, Graduate School of Science, Toho University, Chiba, Japan
| | - Takako Morimoto
- Laboratory of Molecular Neuroscience and Neurology, School of Life Sciences, University of Pharmacy and Life Sciences, Tokyo, Japan
| |
Collapse
|
23
|
Suzuki T, Kohyama K, Moriyama K, Ozaki M, Hasegawa S, Ueno T, Saitoe M, Morio T, Hayashi M, Sakuma H. Extracellular ADP augments microglial inflammasome and NF-κB activation via the P2Y12 receptor. Eur J Immunol 2019; 50:205-219. [PMID: 31549730 DOI: 10.1002/eji.201848013] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2018] [Revised: 07/31/2019] [Accepted: 09/23/2019] [Indexed: 12/11/2022]
Abstract
The NLRP3 inflammasome is a molecular complex that translates signals from pathogens and tissue damage into inflammatory responses, and plays crucial roles in numerous neurological diseases. Activation of the NLRP3 inflammasome leads to caspase-1 dependent cleavage of pro-IL-1β to form mature IL-1β. By acting on the P2X7 purinergic receptor, extracellular ATP is one of the major stimuli that activates the NLRP3 inflammasome. Although microglia express multiple purinergic receptors, their roles in inflammasome-mediated inflammation are largely unknown. We studied the role of the P2Y12 receptor, a metabotropic P2Y receptor enriched in microglia, on inflammation in vitro. Inhibition of the microglial P2Y12 receptor by PSB0739 or siRNA knockdown suppressed IL-1β release. P2Y12 receptor-deficient microglia displayed markedly attenuated IL-1β mRNA expression and release. P2Y12 receptor blockade also suppressed IL-6 production. Both IL-1β and IL-6 responses were augmented by extracellular ADP or ADP-βS and were abrogated by PSB0739. Mechanistically, ADP-βS potentiated NF-κB activation. In addition, ADP altered mitochondrial membrane potential in combination with ATP and increased the number of caspase-1 positive cells through the P2Y12 receptor. These results elucidate a novel inflammatory mechanism by which extracellular ADP acts on the P2Y12 receptor to activate NF-κB and the NLRP3 inflammasome to enhance microglial inflammation.
Collapse
Affiliation(s)
- Tomonori Suzuki
- Developmental Neuroimmunology Project, Department of Brain Development and Neural Regeneration, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.,Department of Pediatrics and Developmental Biology, Bio-Environmental Response Division, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - Kuniko Kohyama
- Developmental Neuroimmunology Project, Department of Brain Development and Neural Regeneration, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
| | - Kengo Moriyama
- Developmental Neuroimmunology Project, Department of Brain Development and Neural Regeneration, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
| | - Mariko Ozaki
- Developmental Neuroimmunology Project, Department of Brain Development and Neural Regeneration, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
| | - Setsuko Hasegawa
- Developmental Neuroimmunology Project, Department of Brain Development and Neural Regeneration, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
| | - Taro Ueno
- Learning and Memory Project, Department of Dementia and Higher Brain Function, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
| | - Minoru Saitoe
- Learning and Memory Project, Department of Dementia and Higher Brain Function, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
| | - Tomohiro Morio
- Department of Pediatrics and Developmental Biology, Bio-Environmental Response Division, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
| | - Masaharu Hayashi
- Developmental Neuroimmunology Project, Department of Brain Development and Neural Regeneration, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
| | - Hiroshi Sakuma
- Developmental Neuroimmunology Project, Department of Brain Development and Neural Regeneration, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan
| |
Collapse
|
24
|
Ota K, Ueno T, Nakanishi T, Nakano T, Yamashita T, Yoshimi M, Fujita A, Okabayashi H, Tao Y, Takata S. Evaluating the prevalence of the expression of PD-L1 in NSCLC specimens with short-duration formalin fixation using IHC 22C3 pharmDx. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz269.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
25
|
Mori D, Miyagawa S, Kawamura T, Hata H, Ueno T, Toda K, Kuratani T, Kurata H, Nishida H, Sawa Y. P315In-vivo and vitro mitochondrial transfer from adipose-derived mesenchymal stem cell to ischemic cardiomyocyte. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Although transplantation of human Adipose-derived Mesenchymal stem cell (hADSC) shows efficacy in the treatment of ischemic cardiomyopathy, its therapeutic mechanisms have not been fully elucidated. It has been already reported that mitochondria transfer to recipient cells have impact on resistance to injury and tissue regeneration, however this phenomenon has not been elucidated in the damaged heart. Therefore, we hypothesized that ADSC transfer own mitochondria to cardiomyocytes in-vivo and in-vitro under ischemic condition, resulting in the functional recovery of cardiomyocyte.
Method and result
Transplantation of hADSC (group A) to the heart surface or sham operation (group C) was performed in rats that were subjected to LAD ligation 2 weeks prior to the treatment (n=10 each). The number of transplant cell was 1x106/body. Three days after transplantation, transferred hADSCs' mitochondria were observed in recipient cardiomyocytes histologically (Figure). Quantitative PCR analysis revealed that mitochondrial genome of recipient myocytes increased over time. The cardiac function assessed with echocardiography was significantly better in group A. Furthermore, live-imaging of hADSC transplantation revealed the suspected transfer of mitochondria to beating heart.
In-vitro, the co-culture of rat cardiomyocytes (rCM) and hADSC was observed with time-lapse photography and demonstrated mitochondrial transfer under the hypoxic condition. The measuring the oxygen consumption rate (OCR) of these cells showed that OCR of rCM was reinforced by co-culture with hADSC conspicuously.
Figure 1
Conclusion
Mitochondrial transfer from hADSC to rCM was suggested in-vivo and in-vitro ischemic condition and suspected to be related to functional recovery of ischemic cardiomyocyte.
Collapse
Affiliation(s)
- D Mori
- Osaka University Graduate School of Medicine, Osaka, Japan
| | - S Miyagawa
- Osaka University Graduate School of Medicine, Osaka, Japan
| | - T Kawamura
- Osaka University Graduate School of Medicine, Osaka, Japan
| | - H Hata
- Osaka University Graduate School of Medicine, Osaka, Japan
| | - T Ueno
- Osaka University Graduate School of Medicine, Osaka, Japan
| | - K Toda
- Osaka University Graduate School of Medicine, Osaka, Japan
| | - T Kuratani
- Osaka University Graduate School of Medicine, Osaka, Japan
| | - H Kurata
- Osaka University Graduate School of Medicine, Osaka, Japan
| | - H Nishida
- Osaka University Graduate School of Medicine, Osaka, Japan
| | - Y Sawa
- Osaka University Graduate School of Medicine, Osaka, Japan
| |
Collapse
|
26
|
Goto T, Miyagawa S, Tamai K, Matsuura R, Harada A, Ueno T, Toda K, Kuratani T, Sawa Y. P5391Systemic administration of high-mobility group box 1 can suppress adverse post-infarction ventricular remodeling in a rat infarction model by enhancing self-regeneration. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
High-mobility group box 1 protein (HMGB1) reportedly enhances CXCR4-positive bone marrow-derived mesenchymal stem cell (BM-MSC) recruitment to damaged tissue to promote tissue regeneration.
Purpose
Our aim of this study is to evaluate whether systemic administration of HMGB1 might promote tissue repair in a rat myocardial infarction (MI) model.
Methods
We prepared 26 MI model rats with high ligation of the left coronary artery. Two weeks later, HMGB1 (3 mg/kg/day) or phosphate-buffered saline (control: 3 mL/kg/day) was administered for 4 days via femoral vein. Cardiac performance was evaluated by ultrasonography, left ventricular (LV) remodeling via immunostaining. We then used immunostaining to examine MSC recruitment to damaged tissue in green fluorescent protein bone marrow transplantation (GFP-BMT) model rats, and also performed intravital imaging using two-photon microscopy to visualize BM-cells recruitment in real time.
Results
Compared with control rats, there was a significant improvement in the left ventricular ejection fraction of the HMGB1 group (HMGB1 vs. control: 48.6% ± 5.5% vs. 33.6% ± 5.4%; p<0.01) at 4 weeks after each administration. LV remodeling, characterized by interstitial fibrosis, cardiomyocyte hypertrophy, and a decrease of capillary density, was significantly attenuated in the HMGB1 group compared with control rats. On QT-PCR analysis, VEGF mRNA expression was significantly higher in the HMGB1 group than in the control (border zone; 1.6±0.6 vs. 1.1±0.2; p=0.02, septal zone; 1.1±0.1 vs. 0.9±0.1; p<0.01). In GFP-BMT rats, GFP+/PDGFR+ cells were significantly mobilized to the border zone in the HMGB1 group compared with the control (1331±197 vs. 615±45 /mm2; p<0.01), leading to formation of newly developed vasculature (Figure 1). In intravital imaging, more GFP+ cells were mobilized to the infarction area in the HMGB1 group than in the control, which was further enhanced at 12h later. Additionally, SDF-1 expression in the peri-infarction area increased significantly in MI rats compared with normal rats (MI vs. normal; 2.1±0.4 vs. 0.9±0.1; p<0.01), in where some cell-adhesions of vascular endothelial cells were destroyed.
Conclusions
Systemic administration of HMGB1 mobilized BM-MSCs to the damaged myocardium via the SDF-1/CXCR4 signaling complex. Those BM-MSCs might migrate to extracellular matrix in the border zone via the gap of each endothelial cell, leading to induction of angiogenesis and reduced fibrosis.
Acknowledgement/Funding
None
Collapse
Affiliation(s)
- T Goto
- Osaka University Graduate School of Medicine, Suita, Japan
| | - S Miyagawa
- Osaka University Graduate School of Medicine, Suita, Japan
| | - K Tamai
- Osaka University Graduate School of Medicine, Department of Stem Cell Therapy Science, Osaka, Japan
| | - R Matsuura
- Osaka University Graduate School of Medicine, Suita, Japan
| | - A Harada
- Osaka University Graduate School of Medicine, Suita, Japan
| | - T Ueno
- Osaka University Graduate School of Medicine, Suita, Japan
| | - K Toda
- Osaka University Graduate School of Medicine, Suita, Japan
| | - T Kuratani
- Osaka University Graduate School of Medicine, Department of Minimally Invasive Cardiovascular Medicine, Osaka, Japan
| | - Y Sawa
- Osaka University Graduate School of Medicine, Suita, Japan
| |
Collapse
|
27
|
Tsuboi M, Kenmotsu H, Yamanaka T, Yoshiya K, Takahashi T, Ueno T, Goto K, Daga H, Ikeda N, Sugio K, Seto T, Toyooka S, Date H, Mitsudomi T, Okamoto I, Yokoi K, Saka H, Okamoto H, Takiguchi Y, Yamamoto N. JIPANG study: Randomized phase III study of pemetrexed/cisplatin (PEM/Cis) versus vinorelbine /cisplatin (VNR/Cis) for completely resected p-stage II-IIIA non-squamous non-small cell lung cancer (Ns-NSCLC): Outcomes based on EGFR mutation status. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz258.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
28
|
Baba F, Shibamoto Y, Iwana M, Nomura K, Nagayoshi J, Ono Y, Akiyama K, Yamamoto T, Saito K, Fujioka R, Ueno T. Evaluation of Changes in Respiratory Patterns by Repeating under Different Respiratory Conditions. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
29
|
Tsuji K, Ochi E, Okubo R, Shimizu Y, Kuchiba A, Ueno T, Shimazu T, Kinoshita T, Sakurai N, Matsuoka Y. Effect of home-based high-intensity interval training and behavioural modification using information and communication technology on cardiorespiratory fitness and exercise habits among sedentary breast cancer survivors: habit-B study protocol for a randomised controlled trial. BMJ Open 2019; 9:e030911. [PMID: 31444192 PMCID: PMC6707761 DOI: 10.1136/bmjopen-2019-030911] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
INTRODUCTION Maintaining high levels of physical activity helps to maintain and improve physical health and quality of life, and plays a role in reducing adverse effects due to cancer treatments. Moreover, a greater degree of cardiorespiratory fitness is associated with reduced risk of all-cause mortality. However, there are no home-based programme for improving cardiorespiratory fitness using body weight exercises for breast cancer survivors. This study will assess the efficacy of the newly developed habit-B programme on maximum oxygen uptake compared with treatment as usual with wearable device. The effects of this programme on exercise habits, level of physical activity, physical fitness and subjective indices will also be investigated. METHODS AND ANALYSIS This is a 12-week, parallel-group, single-blind, randomised controlled trial. Allocation will be managed by a central server using a computer-generated random allocation sequence provided by an independent data centre. Participants will be assigned to the habit-B programme (high-intensity interval training, exercise counselling + guidance, home-based exercise support using information and communication technology, and a wearable device) or treatment as usual with a wearable device. Subjects will be sedentary women aged 20-59 years who have received breast surgery in the past 2-13 months after the diagnosis of invasive breast cancer (stages I-IIa) and have never received chemotherapy except for hormone therapy. The primary endpoint is the change in peak oxygen uptake (VO2peak; mL/kg/min) between the groups after 12 weeks of intervention. ETHICS AND DISSEMINATION The study protocol was approved by the Institutional Review Board of the National Cancer Center Japan on 28 February 2019 (ID: 2018-347). The findings will be disseminated through peer-reviewed publications and conference presentations. TRIAL REGISTRATION NUMBER UMIN000036400.
Collapse
Affiliation(s)
- Katsunori Tsuji
- Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
| | - Eisuke Ochi
- Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
- Faculty of Bioscience and Applied Chemistry, Hosei University, Koganei, Tokyo, Japan
| | - Ryo Okubo
- Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
| | - Yoichi Shimizu
- Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
| | - Aya Kuchiba
- Division of Biostatistical Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
- Biostatistics Division, Center for Research Administration and Support, National Cancer Center Japan, Tokyo, Japan
| | | | - Taichi Shimazu
- Division of Prevention, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
| | - Takayuki Kinoshita
- Department of Breast Surgery, National Cancer Center Hospital, Tokyo, Japan
| | | | - Yutaka Matsuoka
- Division of Health Care Research, Center for Public Health Sciences, National Cancer Center Japan, Tokyo, Japan
- Lifestyle Medicine, Cooperative Graduate Program, The Jikei University Graduate School of Medicine, Tokyo, Japan
| |
Collapse
|
30
|
Nagasaka T, Tanioka H, Nyuya A, Katata Y, Okawaki M, Yamamura M, Kawai T, Yasui K, Toshima T, Mori Y, Umeda Y, Tsuruta A, Ueno T, Yamaguchi Y. Poor prognosis of hypermutant colorectal cancer with KRAS mutations: A retrospective analysis of 1,052 Japanese colorectal cancer patients without treatment of immuno-checkpoint inhibitors. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.260] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Ochi A, Sekiguchi M, Tsujimura K, Kinoshita T, Ueno T, Katayama Y. Two Cases of Equine Multinodular Pulmonary Fibrosis in Japan. J Comp Pathol 2019; 170:46-52. [PMID: 31375158 DOI: 10.1016/j.jcpa.2019.05.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2019] [Revised: 04/20/2019] [Accepted: 05/14/2019] [Indexed: 11/28/2022]
Abstract
Equine multinodular pulmonary fibrosis (EMPF) is a recently described form of interstitial pneumonia associated with equine herpesvirus type 5 (EHV-5). This disease has been reported in North and South America, Europe and Oceania but not, to our knowledge, in horses in Japan. We diagnosed EMPF in two Thoroughbred horses in Japan on the basis of gross and histopathological findings. In both cases, significant gross lesions, restricted to the lungs, consisted of numerous firm and coalescing nodules widely distributed throughout the lung. The nodules were <3 cm in diameter and pale white to tan in colour. Microscopically, they showed severe interstitial fibrosis and infiltration of macrophages, neutrophils, lymphocytes and a few eosinophils. The residual alveoli were lined by cuboidal epithelial cells (type II pneumocytes) and filled with many macrophages, which rarely displayed oval eosinophilic to amphophilic intranuclear inclusion bodies. Polymerase chain reaction and sequence analyses identified the glycoprotein H gene of EHV-5, and in-situ hybridization detected EHV-5 in the alveolar macrophages in the lesions. In one case, electron microscopy revealed herpesvirus-like particles and EHV-5 was isolated from pulmonary lesions.
Collapse
Affiliation(s)
- A Ochi
- Equine Research Institute, Japan Racing Association, 1400-4, Shiba, Shimotsuke, Tochigi, Japan
| | - M Sekiguchi
- Chuo Livestock Hygiene Service Office of Chiba Prefecture, 497 Iwatomi-machi, Sakura, Chiba, Japan.
| | - K Tsujimura
- Equine Research Institute, Japan Racing Association, 1400-4, Shiba, Shimotsuke, Tochigi, Japan
| | - T Kinoshita
- Chuo Livestock Hygiene Service Office of Chiba Prefecture, 497 Iwatomi-machi, Sakura, Chiba, Japan
| | - T Ueno
- Equine Research Institute, Japan Racing Association, 1400-4, Shiba, Shimotsuke, Tochigi, Japan
| | - Y Katayama
- Equine Research Institute, Japan Racing Association, 1400-4, Shiba, Shimotsuke, Tochigi, Japan
| |
Collapse
|
32
|
Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L. Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. Ann Oncol 2019; 30:1018. [PMID: 30624555 DOI: 10.1093/annonc/mdy530] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Motohashi T, Hirano T, Okumura K, Kashiyama M, Ichikawa D, Ueno T. Secure and Scalable mHealth Data Management Using Blockchain Combined With Client Hashchain: System Design and Validation. J Med Internet Res 2019; 21:e13385. [PMID: 31099337 PMCID: PMC6542324 DOI: 10.2196/13385] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2019] [Revised: 03/23/2019] [Accepted: 04/27/2019] [Indexed: 11/23/2022] Open
Abstract
Background Blockchain is emerging as an innovative technology for secure data management in many areas, including medical practice. A distributed blockchain network is tolerant against network fault, and the registered data are resistant to tampering and revision. The technology has a high affinity with digital medicine like mobile health (mHealth) and provides reliability to the medical data without labor-intensive third-party contributions. On the other hand, the reliability of the medical data is not insured before registration to the blockchain network. Furthermore, there are issues with regard to how the clients' mobile devices should be dealt with and authenticated in the blockchain network in order to avoid impersonation. Objective The aim of the study was to design and validate an mHealth system that enables the compatibility of the security and scalability of the medical data using blockchain technology. Methods We designed an mHealth system that sends medical data to the blockchain network via relay servers. The architecture provides scalability and convenience of operation of the system. In order to ensure the reliability of the data from clients' mobile devices, hash values with chain structure (client hashchain) were calculated in the clients' devices and the results were registered on the blockchain network. Results The system was applied and deployed in mHealth for insomnia treatment. Clinical trials for mHealth were conducted with insomnia patients. Medical data of the recruited patients were successfully registered with the blockchain network via relay servers along with the hashchain calculated on the clients' mobile devices. The correctness of the data was validated by identifying illegal data, which were made by simulating fraudulent access. Conclusions Our proposed mHealth system, blockchain combined with client hashchain, ensures compatibility of security and scalability in the data management of mHealth medical practice. Trial Registration UMIN Clinical Trials Registry UMIN000032951; https://upload.umin.ac.jp/cgi-open- bin/ctr_e/ctr_view.cgi?recptno=R000037564 (Archived by WebCite at http://www.webcitation.org/78HP5iFIw)
Collapse
|
34
|
Maeda S, Toda K, Hata H, Miyagawa S, Yoshikawa Y, Kainuma S, Kawamura T, Kawamura A, Yoshida S, Ueno T, Kuratani T, Sawa Y. Valvular Disease Management in Patients with Continuous-Flow Left Ventricular Assist Device. J Heart Lung Transplant 2019. [DOI: 10.1016/j.healun.2019.01.906] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
35
|
Akiyoshi S, Kobayashi K, Kobayashi T, Hosonaga M, Kitagawa D, Ito T, Ueno T, Ohno S. Anthracycline followed by trastuzumab is still one of treatment options for small tumor with node-negative HER2-positive breast cancer. Breast 2019. [DOI: 10.1016/s0960-9776(19)30117-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
36
|
Imoto S, Futamura M, Toi M, Fujiwara Y, Ueno T, Im YH, Im SA, Ahn SG, Lee JE, Park YH, Wang K, Kitagawa Y, Nishiyama M. Abstract OT2-05-02: International retrospective cohort study of locoregional and systemic therapy in oligometastatic breast cancer (OLIGO-BC1). Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-ot2-05-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Breast cancer (BC) is so-called “systemic disease”, because disseminated cancer cells in bone marrow and blood are detected even in early BC patients. Despite adjuvant therapy and postoperative radiation therapy, patients with triple negative BC and Luminal B-like BC often relapse early and systemic therapy is the only way to control disease progression. On the other hand, some BC patients relapse several years later. In such patients, oligometastases are occasionally diagnosed, because metastatic cancer cells are slowly growing and indolent. Oligometastatic BC is defined as low volume metastatic disease with limited number and size of metastatic lesions (up to five and not necessarily in the same organ). This definition is proposed in the Advanced Breast Cancer guidelines that are developed as a joint effort from European School of Oncology and European Society of Medical Oncology. Several retrospective studies demonstrated survival benefit of locoregional therapy in addition to systemic therapy. Locoregional therapy consisted of surgical resection, radiation therapy, ablation therapy, etc. However, it remains unclear about survival benefit of combined therapy in oligometastatic BC. To improve the standard of cancer treatment through the cooperate studies on more effective therapeutic strategies based on drugs, surgery and/or radiotherapy, Federation of Asian Clinical Oncology (FACO) was established in 2012 by Chinese Society of Clinical Oncology (CSCO), Korean Society of Medical Oncology (KSMO) and Japan Society of Clinical Oncology (JSCO). Thus, FACO conducted a retrospective cohort study on oligometastatic BC. The primary endpoint is to compare the estimated 5-year overall survival (OS) of oligometastatic BC patients treated with combined therapy and systemic therapy alone. To hypothesize that combined therapy has more advantage of OS in oligometastatic BC, the 5-year OS rates are expected to be 50% and 40%, respectively. The estimated sample size is calculated to be the number of 698 cases (349 cases in each group) needed to prove the superiority of survival with a two-sided type I error rate of 5% and a statistical power of 80%. Case registry opened in February 2018 and will close in January 2019. We planned to register 700 cases, i.e., 234 cases each from investigators of CSCO, KSMO and JSCO. Update information will be discussed.
Citation Format: Imoto S, Futamura M, Toi M, Fujiwara Y, Ueno T, Im Y-H, Im S-A, Ahn SG, Lee JE, Park YH, Wang K, Kitagawa Y, Nishiyama M. International retrospective cohort study of locoregional and systemic therapy in oligometastatic breast cancer (OLIGO-BC1) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr OT2-05-02.
Collapse
Affiliation(s)
- S Imoto
- Kyorin University School of Medicine, Mitaka, Japan; Gifu University School of Medicine, Gifu, Japan; Kyoto University School of Medicine, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Guangdong General Hospital, Guangzhou, China; Keio University School of Medicine, Tokyo, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan
| | - M Futamura
- Kyorin University School of Medicine, Mitaka, Japan; Gifu University School of Medicine, Gifu, Japan; Kyoto University School of Medicine, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Guangdong General Hospital, Guangzhou, China; Keio University School of Medicine, Tokyo, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan
| | - M Toi
- Kyorin University School of Medicine, Mitaka, Japan; Gifu University School of Medicine, Gifu, Japan; Kyoto University School of Medicine, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Guangdong General Hospital, Guangzhou, China; Keio University School of Medicine, Tokyo, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Y Fujiwara
- Kyorin University School of Medicine, Mitaka, Japan; Gifu University School of Medicine, Gifu, Japan; Kyoto University School of Medicine, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Guangdong General Hospital, Guangzhou, China; Keio University School of Medicine, Tokyo, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan
| | - T Ueno
- Kyorin University School of Medicine, Mitaka, Japan; Gifu University School of Medicine, Gifu, Japan; Kyoto University School of Medicine, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Guangdong General Hospital, Guangzhou, China; Keio University School of Medicine, Tokyo, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Y-H Im
- Kyorin University School of Medicine, Mitaka, Japan; Gifu University School of Medicine, Gifu, Japan; Kyoto University School of Medicine, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Guangdong General Hospital, Guangzhou, China; Keio University School of Medicine, Tokyo, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan
| | - S-A Im
- Kyorin University School of Medicine, Mitaka, Japan; Gifu University School of Medicine, Gifu, Japan; Kyoto University School of Medicine, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Guangdong General Hospital, Guangzhou, China; Keio University School of Medicine, Tokyo, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan
| | - SG Ahn
- Kyorin University School of Medicine, Mitaka, Japan; Gifu University School of Medicine, Gifu, Japan; Kyoto University School of Medicine, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Guangdong General Hospital, Guangzhou, China; Keio University School of Medicine, Tokyo, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan
| | - JE Lee
- Kyorin University School of Medicine, Mitaka, Japan; Gifu University School of Medicine, Gifu, Japan; Kyoto University School of Medicine, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Guangdong General Hospital, Guangzhou, China; Keio University School of Medicine, Tokyo, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan
| | - YH Park
- Kyorin University School of Medicine, Mitaka, Japan; Gifu University School of Medicine, Gifu, Japan; Kyoto University School of Medicine, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Guangdong General Hospital, Guangzhou, China; Keio University School of Medicine, Tokyo, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan
| | - K Wang
- Kyorin University School of Medicine, Mitaka, Japan; Gifu University School of Medicine, Gifu, Japan; Kyoto University School of Medicine, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Guangdong General Hospital, Guangzhou, China; Keio University School of Medicine, Tokyo, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan
| | - Y Kitagawa
- Kyorin University School of Medicine, Mitaka, Japan; Gifu University School of Medicine, Gifu, Japan; Kyoto University School of Medicine, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Guangdong General Hospital, Guangzhou, China; Keio University School of Medicine, Tokyo, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan
| | - M Nishiyama
- Kyorin University School of Medicine, Mitaka, Japan; Gifu University School of Medicine, Gifu, Japan; Kyoto University School of Medicine, Kyoto, Japan; National Cancer Center Hospital, Tokyo, Japan; Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; Sungkyunkwan University School of Medicine, Seoul, Korea; Seoul National University, Seoul, Korea; Yonsei University College of Medicine, Seoul, Korea; Guangdong General Hospital, Guangzhou, China; Keio University School of Medicine, Tokyo, Japan; Gunma University Graduate School of Medicine, Maebashi, Japan
| |
Collapse
|
37
|
Abe T, Ito Y, Fukada I, Shibayama T, Ono M, Kobayashi T, Kobayashi K, Takahashi S, Horii R, Akiyama F, Iwase T, Ueno T, Ohno S. Abstract P4-08-29: Lymphatic invasion is an independent risk factor in patients with small node-negative luminal breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-08-29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
[Background]
In patients with node-negative (N0), hormone receptor-positive, human epidermal growth factor receptor (HER2) -negative (luminal) breast cancer, the impact of lymphatic invasion (ly) on the prognosis remains to be clarified.
[Methods]
Among 3,158 patients with primary breast cancers who underwent surgery in our institute from January 2007 to December 2009, we analyzed 1027 N0 luminal invasive breast cancers without preoperative systemic therapy. The luminal breast cancer was defined as hormone receptor-positive (ER of ≥ 10% or PgR of ≥ 10%) and HER2-negative (immunohistochemistry: 0, 1+ or FISH: ratio < 2.0) cancer in the postoperative pathological specimen. ly was defined as positive when cancer cell nests were detected within the lymph duct in the whole specimen. N0 was confirmed pathologically by the sentinel lymph node biopsy in all the patients. The Fisher's exact test was used for comparison between different categories. The distant recurrence rate (DRR) was analyzed using the Kaplan-Meier method and the log-rank test. For multivariate analysis, Cox's regression analysis was performed.
[Results]
The median follow-up period was 103.8 months (range: 5.6-128.8). Recurrence with distant metastasis occurred in 26 patients (2.5%). There were 5 (0.7%) deaths related to breast cancer. ly was detected in 240 patients (23.4%). In the ly-positive group, the tumor size was larger (p = 0.007), and the nuclear grade (NG) was higher (p < 0.001) than in the ly-negative group. Postoperative endocrine therapy (p < 0.001) and postoperative chemotherapy (p < 0.001) were more frequently employed for patients with ly-positive tumor. The univariate analysis showed that ly positivity (p < 0.001), large tumor size (p < 0.001), high NG (p < 0.001), PgR negativity (p = 0.002) and the history of adjuvant chemotherapy (p < 0.001) were associated with high DRR. In the multivariate analysis, large tumor size (p = 0.007) and PgR negativity (p = 0.015) remained significant. Although positive ly had a risk ratio of 2.2, it was not an independent risk factor.When restricted to T1 tumor (n = 899), the aforementioned factors still showed prognostic value in the univariate analysis, among which ly positivity (p = 0.004)remained significant together with PgR negativity (p = 0.047)in themultivariate analysis.The 8-year DRR was very favorable (0.8%) in patients with ly-negative T1N0 tumor while it was modest (6.6%) in patients with ly-positive T1N0 tumor (p < 0.001). Only 1.3% of the patients had received adjuvant chemotherapy in the ly-negative group while 27% of the patients had in the ly-positive group.
[Conclusion]
Lymphatic invasion was associated with higher DRR although it was not independent in the multivariate analysis among patients with N0 luminal breast cancer. When restricted to patients with T1N0 luminal breast cancer, the presence of ly was independently associated with higher risk of distant recurrence. It suggests that the assessment of ly is clinically more relevant when considering treatment options for small luminal breast cancer.
Citation Format: Abe T, Ito Y, Fukada I, Shibayama T, Ono M, Kobayashi T, Kobayashi K, Takahashi S, Horii R, Akiyama F, Iwase T, Ueno T, Ohno S. Lymphatic invasion is an independent risk factor in patients with small node-negative luminal breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-08-29.
Collapse
Affiliation(s)
- T Abe
- Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute, the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - Y Ito
- Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute, the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - I Fukada
- Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute, the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - T Shibayama
- Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute, the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - M Ono
- Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute, the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - T Kobayashi
- Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute, the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - K Kobayashi
- Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute, the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - S Takahashi
- Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute, the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - R Horii
- Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute, the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - F Akiyama
- Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute, the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - T Iwase
- Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute, the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - T Ueno
- Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute, the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - S Ohno
- Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute, the Japanese Foundation for Cancer Research, Tokyo, Japan
| |
Collapse
|
38
|
Yonekura R, Osako T, Iwase T, Ogiya A, Ueno T, Ohno S, Akiyama F. Abstract P5-18-11: Prognostic impact and possible pathogenesis of lymph node metastasis in ductal carcinoma in situof the breast. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p5-18-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: By definition, ductal carcinoma in situ (DCIS) does not metastasize to the lymph nodes. However, since the introduction of molecular whole-node analysis using the one-step nucleic acid amplification (OSNA) assay for sentinel node (SN) biopsies, the number of DCIS patients with SN metastasis has increased. The clinical management of node-positive DCIS remains controversial because these patients can be treated as different stages based on the pathogenesis: e.g. occult invasive cancer with true nodal metastasis (T1N1) or true DCIS with iatrogenic dissemination of benign or tumor cells into lymph node (TisN0). In this retrospective cohort study, we aimed to elucidate the pathogenesis of nodal metastasis in DCIS and the clinical management of node-positive DCIS.
Patients and Methods: Subjects comprised of 427 patients with a routine postoperative diagnosis of DCIS who underwent SN biopsy using the OSNA assay between 2009 and 2012. The cut-off values of the OSNA assay for negative/positive results and micro/macrometastasis were defined at 250 and 5,000 copies/μL of cytokeratin 19 mRNA, respectively. In the SN-positive patients, all paraffin blocks containing the primary tumor were step-sectioned with 0.5-mm intervals until the tissue was exhausted, and all microscopic slides were examined for detecting occult invasions. Afterwards, the patients were classified into three cohorts based on the SN status and occult invasion: (1) no SN metastasis (TisN0), (2) SN metastasis without occult invasion (TisN1), and (3) SN metastasis with occult invasion (T1N1). Tumor characteristics including risk factors of occult invasions (e.g. large size, comedo-type), prognosis, and SN and non-SN status were compared among the three cohorts. The median follow-up time was 73.6 months.
Results: Of the 427 patients, 408 (95.6%) were SN-negative and 19 (4.4%) were SN-positive. By examining a total of 1,421 step-sectioned slides, 9 of the 19 SN-positive patients had occult invasions in the primary tumors. Overall, 408 (95.6%), 10 (2.3%), and 9 (2.1%) were classified into the TisN0, TisN1, and T1N1 cohorts, respectively. Either of adjuvant endocrine therapy or chemotherapy was given much more in the TisN1 and T1N1 cohorts than in the TisN0 cohort (80.0% and 88.9% vs. 5.4%).Other tumor characteristics were similar among the three cohorts. Although one patients had distant recurrence in the TisN0 cohort, none had locoregional or distant recurrences in the TisN1 and T1N1 cohorts. Regarding the lymph node status in the TisN1 and T1N1 cohorts, median tumor burdens in the SN are 590 and 310 copies/μL, and 2 (20.0%) and 2 (22.2%) patients had additional non-SN metastasis in the axillary dissection materials, respectively.
Conclusions: Tumor characteristics and prognosis were similar among the three cohorts albeit the TisN1 and T1N1 cohorts tended to received adjuvant systemic therapy. Moreover, the SN and non-SN status were similar between the TisN1 and T1N1 cohorts. Therefore, pathogenesis of nodal metastasis in DCIS cannot uniformly be explained, and tumors with different stages may be mixed in the node-positive DCIS. Thus, considering the favorable prognosis of node-positive DCIS, the clinical management should be determined on a case-by-case basis.
Citation Format: Yonekura R, Osako T, Iwase T, Ogiya A, Ueno T, Ohno S, Akiyama F. Prognostic impact and possible pathogenesis of lymph node metastasis in ductal carcinoma in situof the breast [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P5-18-11.
Collapse
Affiliation(s)
- R Yonekura
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute of the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - T Osako
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute of the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - T Iwase
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute of the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - A Ogiya
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute of the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - T Ueno
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute of the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - S Ohno
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute of the Japanese Foundation for Cancer Research, Tokyo, Japan
| | - F Akiyama
- The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute of the Japanese Foundation for Cancer Research, Tokyo, Japan
| |
Collapse
|
39
|
Osako T, Iwase T, Ushijima M, Ogiya A, Ueno T, Ohno S, Akiyama F. Abstract P3-03-23: Which factor of metastatic lymph nodes–The number, tumor volume or anatomical location–Is independently prognostic in breast cancer? - A prospective cohort study using molecular whole-node analysis of all removed axillary nodes. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-03-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Axillary lymph node status is one of the most powerful prognostic factors in breast cancer. However, it remains unknown which factor of metastatic lymph nodes–the number, tumor volume or anatomical location–is independently prognostic. Conventional pathological examinations of lymph nodes have limited ability to accurately measure metastatic tumor volume due to the partial evaluation of nodes. On the other hand, the one-step nucleic acid amplification (OSNA) assay, a novel molecular method, can quantify the tumor volume in a whole node based on cytokeratin 19 (CK19) mRNA copy number. In this prospective cohort studyusing the OSNA whole-node analysis, we aimed to elucidate the independent prognostic factor of lymph node metastasis in breast cancer.
Patients and Methods: The subjects consisted of 307 cN0 patients with invasive breast cancer, who underwent axillary dissection after a metastatic sentinel node (SN) biopsy and whose SNs and non-SNs were all examined using the OSNA whole-node assaybetween 2009 and 2012.The cut-off values of the OSNA assay for negative/positive results and micro/macrometastasis were defined at 250 and 5,000 copies/μL of CK19 mRNA, respectively. The total tumor volume in the SN or non-SN was defined as the sum of CK19 mRNA copy numbers from all samples in the SN or non-SN. The cut-off value for the total tumor volume in the SN was set at 2,810 copies/μL according to our previous study (Osako et al. Br J Cancer 2017). The anatomical location of metastasis was classified into Level I (confined to SN), Level I (spread to non-SN), or Level II/III. Predictive factors for distant disease-free survival (DDFS) were investigated using the univariate log-rank tests and multivariate Cox proportional hazards models.The median follow-up time was 6.1 years (range, 0.2–8.6).
Results: Of the 307 patients, 130 (42.3%) and 177 (57.7%) had the total tumor volume <2,810 and ≥2,810 copies/μL in the SN, respectively. Five-year DDFS was 96.0% in the entire cohort. In the univariate analysis, DDFS was significantly related to the pT classification, grade, hormone receptor status, triple-negative subtype, total tumor volume in the SN and cytotoxic chemotherapy. However, DDFS was not significantly related to the number of metastatic or macrometastatic nodes in the SN, non-SN, or all nodes (i.e. SN + non-SN); the total tumor volume in the non-SN or all nodes; the AJCC pN classification; or the anatomical location of metastasis. In the multivariate analysis, the total tumor volume in the SN (<2810 vs. ≥2810 copies/μL, hazard ratio 5.2, 95% confidence interval 1.2–23.2, P=0.03) and cytotoxic chemotherapy (- vs. +, hazard ratio 0.05, 95% confidence interval 0.02–0.17, P<0.001) remained significant.
Conclusions: The total tumor volume in the SN was the independent prognostic factor of lymph node metastasis in SN-positive invasive breast cancer. Accurate evaluation of metastatic tumor burden in the SN can be important for predicting prognosis and may help to guide the precise therapeutic decision making for breast cancer patients.
Citation Format: Osako T, Iwase T, Ushijima M, Ogiya A, Ueno T, Ohno S, Akiyama F. Which factor of metastatic lymph nodes–The number, tumor volume or anatomical location–Is independently prognostic in breast cancer? - A prospective cohort study using molecular whole-node analysis of all removed axillary nodes [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-03-23.
Collapse
Affiliation(s)
- T Osako
- The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - T Iwase
- The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - M Ushijima
- The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - A Ogiya
- The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - T Ueno
- The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - S Ohno
- The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan
| | - F Akiyama
- The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; The Cancer Institute of Japanese Foundation for Cancer Research, Tokyo, Japan
| |
Collapse
|
40
|
Yoshitani J, Kabata T, Kajino Y, Ueno T, Ueoka K, Nakamura T, Tsuchiya H. Morphometric geometrical analysis to determine the centre of the acetabular component placement in Crowe type IV hips undergoing total hip arthroplasty. Bone Joint J 2019; 101-B:189-197. [PMID: 30700119 DOI: 10.1302/0301-620x.101b2.bjj-2018-1076.r1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
AIMS We analyzed the acetabular morphology of Crowe type IV hips using CT data to identify a landmark for the ideal placement of the centre of the acetabular component, as assessed by morphometric geometrical analysis, and its reliability. PATIENTS AND METHODS A total of 52 Crowe IV hips (42 patients; seven male, 35 female; mean age 68.5 years (32 to 82)) and 50 normal hips (50 patients; eight male, 42 female; mean age 60.7 years (34 to 86)) undergoing total hip arthroplasty were retrospectively identified. In this CT-based simulation study, the acetabular component was positioned at the true acetabulum with a radiological inclination of 40° and anteversion of 20°. Acetabular shape and the position of the centre of the acetabular component were analyzed by morphometric geometrical analysis using the generalized Procrustes analysis. RESULTS The acetabular shapes of Crowe IV hips were distinctively triangular; the ideal position of the centre of the acetabular component was superior on the posterior bony wall. The first and second relative warps explained 34.2% and 18.4% of the variance, respectively, compared with that of 28.6% and 18.0% in normal hips. We defined the landmark as one-third the distance from top on the posterior bony wall in Crowe IV hips. The average distance from the centre of the acetabular component was 5.6 mm. CONCLUSION Crowe IV hips are distinctively triangular; the point one-third from the top on the posterior bony wall was a useful landmark for placing the acetabular component.
Collapse
Affiliation(s)
- J Yoshitani
- Department of Orthopaedic Surgery, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
| | - T Kabata
- Department of Orthopaedic Surgery, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
| | - Y Kajino
- Department of Orthopaedic Surgery, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
| | - T Ueno
- Department of Orthopaedic Surgery, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
| | - K Ueoka
- Department of Orthopaedic Surgery, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
| | - T Nakamura
- Department of Orthopedic Surgery, Toyama Prefectural Central Hospital, Toyama, Japan
| | - H Tsuchiya
- Department of Orthopaedic Surgery, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan
| |
Collapse
|
41
|
Ueno T, Osawa M, Shiozaki T, Green M, Garimella T. Exposure-Response Analysis for Efficacy of Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV-Infected Patients. Clin Pharmacol Drug Dev 2019; 8:903-913. [PMID: 30667592 DOI: 10.1002/cpdd.646] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2018] [Accepted: 12/03/2018] [Indexed: 12/21/2022]
Abstract
The combination regimen of daclatasvir, asunaprevir, and beclabuvir (3DAA regimen) was developed as a fixed-dose combination for the treatment of hepatitis C virus (HCV) infection in Japan. The objectives of this analysis were to characterize the relationship between drug exposure and sustained virologic response at posttreatment week 12 (SVR12) in HCV-infected subjects and to evaluate the impact of demographic covariates and clinical factors on the exposure-response (E-R) relationship. The E-R efficacy analysis was performed with data from phase 2 and phase 3 studies in HCV-infected subjects treated with the 3DAA regimen. The relationship between the probability of achieving SVR12 and exposure to daclatasvir, asunaprevir, and beclabuvir was described using a logistic regression model and included assessments of the potential covariate effects. The impacts of the covariates on the rate of SVR12 and interactions of covariates with the individual drug effects were tested. The final model for SVR12 included effects of non-genotype-1a status, resistance-associated NS5A-Q30 substitution in genotype-1a subjects, and baseline RNA level on the intercept, and effect of prior peg-interferon failure on the beclabuvir slope. Sex, race, age, weight, fibrosis score, alanine transaminase, and cirrhosis status had no statistically significant impact on the rate of SVR12. The individual E-R relationships with each drug, were relatively flat, and the effects of exposure were not significant. With the exception of the NS5A-Q30 substitution in genotype-1a subjects, statistically significant covariate effects had little impact on SVR12 rates. Overall, the E-R model was developed that captured the high SVR12 rates and the effect of covariates for the 3DAA regimen in HCV-infected patients.
Collapse
Affiliation(s)
- T Ueno
- Bristol-Myers Squibb KK, Tokyo, Japan
| | - M Osawa
- Bristol-Myers Squibb KK, Tokyo, Japan
| | | | - M Green
- Certara, Menlo Park, CA, USA
| | - T Garimella
- Bristol-Myers Squibb Research and Development, Lawrenceville, NJ, USA
| |
Collapse
|
42
|
Ueno T, Wada M, Hoshino K, Matsuura T, Okajima H, Okuyama H. Impact of Donor Age on Outcome of Intestinal Transplantation in Japan. Transplant Proc 2018; 50:2775-2778. [PMID: 30401396 DOI: 10.1016/j.transproceed.2018.04.021] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2018] [Revised: 03/25/2018] [Accepted: 04/09/2018] [Indexed: 01/10/2023]
Abstract
BACKGROUND Donor age for intestinal transplantation (ITx) is somewhat younger than that for other solid organs. Clear criteria for adequate donors have not been established. There is a donor scarcity for ITx in Japan due to the shortage of young donors. METHODS We reviewed outcomes associated with ITx in Japan based on donor age for cadaveric and living donation. RESULTS Standardized report forms were sent to all known ITx programs, asking for information on ITxs performed between 1996 and 2016. All programs responded. Patient and graft survival estimates were obtained using the Kaplan-Meier method. Five institutions provided data on 27 grafts in 24 patients. There were 14 cadaveric and 13 living donor transplants. Median donor age for ITxs was 40 (range, 17-60) years. Graft survival at 5 years was 66% for patients >40 years old (n = 18) and 47% for those <40 years old (n = 9), not a statistically significant difference (P = .49). Graft survival at 5 years was 60% in those >50 years old (n = 5) and 57% for those <50 years old (n = 22), again not a significant difference (P = .27). CONCLUSION There is no difference in survival between for those with donor age <40 vs >40 years. Donor age for ITx can be extended from >40 to up to 50 years, which may help to mitigate the donor shortage. It will be necessary to clarify the donor criteria for ITx through accumulation of further data on ITx.
Collapse
Affiliation(s)
- T Ueno
- Department of Pediatric Surgery, Osaka University, Osaka, Japan.
| | - M Wada
- Department of Pediatric Surgery, Tohoku University, Miyagi, Japan
| | - K Hoshino
- Department of Pediatric Surgery, Keio University, Tokyo, Japan
| | - T Matsuura
- Department of Pediatric Surgery, Kyushu University, Fukuoka, Japan
| | - H Okajima
- HBP Surgery/Transplantation, Kyoto University, Kyoto, Japan
| | - H Okuyama
- Department of Pediatric Surgery, Osaka University, Osaka, Japan
| |
Collapse
|
43
|
Katata Y, Nagasaka T, Tanioka H, Nyuya A, Toshima T, Mori Y, Shigeyasu K, Okawaki M, Yamamura M, Tsuruta A, Ueno T, Yamaguchi Y. Efficacy of ramucirumab in combination with second-line or salvage-line FOLFIRI in patients with metastatic colorectal cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy431.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
44
|
Ueno T, Wada M, Hoshino K, Matsuura T, Ida S, Okuyama H. Three-Year Prospective Follow-up of Potential Pediatric Candidate for Intestinal Transplantation. Transplant Proc 2018; 50:2779-2782. [DOI: 10.1016/j.transproceed.2018.03.067] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2018] [Accepted: 03/06/2018] [Indexed: 11/16/2022]
|
45
|
Ueno T, Hiwatashi S, Saka R, Yamanaka H, Takama Y, Tazuke Y, Bessho K, Kogaki S, Yonekura T, Okuyama H. Pulmonary Arterial Pressure Management Based on Oral Medicine for Pediatric Living Donor Liver Transplant With Portopulmonary Hypertension. Transplant Proc 2018; 50:2614-2618. [PMID: 30318105 DOI: 10.1016/j.transproceed.2018.03.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2018] [Accepted: 03/02/2018] [Indexed: 11/25/2022]
Abstract
Pediatric living donor liver transplantation (LDLT) in patients with advanced portopulmonary hypertension (PoPH) is associated with poor prognoses. Recently, novel oral medications, including endothelin receptor antagonists (ERAs), phosphodiesterase 5 (PDE5) inhibitors, and oral prostacyclin (PGI2) have been used to treat PoPH. Pediatric patients with PoPH who underwent LDLT from 2006 to 2016 were enrolled. Oral pulmonary hypertension (PH) medication was administered to control pulmonary arterial pressure (PAP). Four patients had PoPH. Their ages ranged from 6 to 16 years, and their original diseases were biliary atresia (n = 2), portal vein obstruction (n = 1), and intrahepatic portal systemic shunt (n = 1). For preoperative management, 2 patients received continuous intravenous PGI2 and 2 oral medications (an ERA alone or an ERA and a PDE5 inhibitor), and 2 received only oral drugs (an ERA and a PDE5 inhibitor). One patient managed only with intravenous PGI2 died. In the remaining 3 cases, intravenous PGI2 or NO was discontinued before the end of the first postoperative week. Postoperative medications were oral PGI2 alone (n = 1), an ERA alone (n = 1), or the combination of an ERA and a PDE5 inhibitor (n = 1). An ERA was the first-line therapy, and a PDE5 inhibitor was added if there was no effect. New oral PH medications were effective and safe for use in pediatric patients following LDLT. In particular, these new oral drugs prevent the need for central catheter access to infuse PGI2.
Collapse
Affiliation(s)
- T Ueno
- Department of Pediatric Surgery, Osaka University Graduate School of Medicine, Suita, Japan.
| | - S Hiwatashi
- Department of Pediatric Surgery, Osaka University Graduate School of Medicine, Suita, Japan
| | - R Saka
- Department of Pediatric Surgery, Osaka University Graduate School of Medicine, Suita, Japan
| | - H Yamanaka
- Department of Pediatric Surgery, Osaka University Graduate School of Medicine, Suita, Japan
| | - Y Takama
- Department of Pediatric Surgery, Osaka University Graduate School of Medicine, Suita, Japan
| | - Y Tazuke
- Department of Pediatric Surgery, Osaka University Graduate School of Medicine, Suita, Japan
| | - K Bessho
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
| | - S Kogaki
- Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan
| | - T Yonekura
- Department of Pediatric Surgery, Kindai University Nara Hospital, Ikoma, Japan
| | - H Okuyama
- Department of Pediatric Surgery, Osaka University Graduate School of Medicine, Suita, Japan
| |
Collapse
|
46
|
Konno O, Yokoyama T, Kihara Y, Nakamura Y, Ueno T, Takeuchi H, Iwamoto H. Early Outcomes of Living-Donor Kidney Transplantation With Immunosuppression Therapy Induction With Tacrolimus Extended-Release: A Comparison With Cyclosporine. Transplant Proc 2018; 50:2457-2460. [PMID: 30316378 DOI: 10.1016/j.transproceed.2018.04.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2018] [Revised: 03/24/2018] [Accepted: 04/09/2018] [Indexed: 11/18/2022]
Abstract
BACKGROUND Extended-release tacrolimus (TacER), administered once daily, offers improved adherence with reduced side effects while still maintaining an immunosuppressive potency equivalent to that of conventional tacrolimus preparations. METHODS The study included 83 patients who received consecutive living-donor kidney transplants at our facility from June 2013 to December 2016. Comparisons were made between 48 cases of induction with TacER and 35 cases of induction with cyclosporine (CyA). The observation period was 3 months after transplantation. Transplanted kidney function, rejection, infectious disease, lipid abnormalities, and glucose tolerance were compared. RESULTS The 2 groups showed no significant difference in donor background or transplanted kidney function. Within the 3-month observation period, an acute rejection response was observed in 2 cases in the TacER group and in 8 cases in the CyA group. After transplantation, hyperlipidemia requiring medication was observed more frequently in the CyA group. The 2 groups did not show a marked difference in systemic infection or renal calcineurin inhibitor toxicity in histopathologic examination of the transplanted kidneys 3 months after surgery. DISCUSSION Proactive use of TacER leads to improved adherence while yielding immunosuppressive potency equivalent to that of conventional tacrolimus preparations; however, tacrolimus has a potent blood sugar-elevating effect; thus, direct comparison with the CyA group is important for assessing the side effects. CONCLUSION TacER has the potential to also reduce side effects in the early stages after surgery, suggesting its potential as a drug of first choice.
Collapse
Affiliation(s)
- O Konno
- Department of Kidney Transplantation Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.
| | - T Yokoyama
- Department of Kidney Transplantation Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan
| | - Y Kihara
- Department of Kidney Transplantation Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan
| | - Y Nakamura
- Department of Kidney Transplantation Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan
| | - T Ueno
- Department of Kidney Transplantation Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan
| | - H Takeuchi
- Department of Kidney Transplantation Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan
| | - H Iwamoto
- Department of Kidney Transplantation Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan
| |
Collapse
|
47
|
Haruki T, Saji H, Ueno T, Okada M, Nakamura H, Chida M. MA01.06 Evaluation of Safety and Efficacy in Surgical Treatment for Octogenarian Lung Cancer Patients by Multicenter Prospective Study: JACS1303. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.317] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
48
|
Yamashita M, Maki Y, Sugimoto R, Ueno T, Toyooka S. P3.17-21 Surgical Treatment for Centrally Located or Hilar Invasive Locally Advanced Lung Cancer. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1977] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
49
|
Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L. Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial. Ann Oncol 2018; 29:2152. [PMID: 29701764 DOI: 10.1093/annonc/mdx805] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
50
|
Nagasaka T, Nyuya A, Tanioka H, Katata Y, Yokota M, Taniguchi F, Kawai T, Mori Y, Shigeyasu K, Okawaki M, Yamamura M, Umeda Y, Tsuruta A, Ueno T, Yamaguchi Y. Distinct clinico-pathological features of hypermutant colorectal cancers with POLE pathogenic mutations, Lynch syndrome and sporadic MSI analyzed over 1,000 colorectal cancer patients. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy281.079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|